Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-12-09
DOI
https://doi.org/10.1056/nejmoa2514663
Citations
9
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
15.93
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Paul A. F. Geerts, Juan Luis Reguera, Roberto Mina, Hamza Hashmi et al.
9 citations
New England Journal of Medicine
Multiple Myeloma Research and Treatments
15.93
article

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Paul A. F. Geerts, Juan Luis Reguera, Roberto Mina, Hamza Hashmi, Luciano J. Costa, Jin Lu, Anne K. Mylin, Gastón Caeiro, Ingrid Maria Cecilia Rubin, Surbhi Sidana, Ajay K. Nooka, María‐Victoria Mateos, Alain Kentos, Meletios Athanasios Dimopoulos, Joaquín Martínez‐López, Magnus Johansson, Charlotte T. Hansen, Donna Reece, Rachel Kobos, Elena van Leeuwen-Segarceanu, Kristen Lantz, Diego Vieyra, Elena Zamagni, Britta Besemer, Raphael Teipel, Mark Grey, Nizar Jacques Bahlis, Agata Tyczyńska, Charlotte Pawlyn, Markus Hansson, Ting Niu, Lijuan Kang, Paula Rodríguez‐Otero, Aurore Perrot, Weili Sun, Kihyun Kım, Mehmet Turgut, Robin Carson, Lisa O’Rourke, Anne Seifert, Chang Ki Min, Satoshi Yoshihara, Vânia Hungria, Deborah Briseno-Toomey
article en
9 citations

Abstract

In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).

New England Journal of MedicineVol. 394(8)
Royal Marsden NHS Foundation Trust (GB), Johnson & Johnson (United States) (US), Memorial Sloan Kettering Cancer Center (US), Emory University (US), University of Calgary (CA), Palo Alto University (US), Korea University (KR), National and Kapodistrian University of Athens (GR), Peking University (CN), Ondokuz Mayıs University (TR), Sichuan University (CN), Sahlgrenska University Hospital (SE), Odense University Hospital (DK), Samsung Medical Center (KR), Princess Margaret Cancer Centre (CA), Rigshospitalet (DK), Centre Hospitalier Universitaire de Toulouse (FR), University of Alabama at Birmingham (US), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Sunderby sjukhus (SE), West China Hospital of Sichuan University (CN), Institute of Cancer Research (CA), Institut universitaire du cancer de Toulouse Oncopole (FR), Piedmont Cancer Institute (US), St. Antonius Ziekenhuis (NL), Hôpital de Jolimont (BE), São Germano Oncologia (BR), Istituto di Ematologia di Bologna (IT), Azienda USL di Bologna (IT), Peking University People's Hospital (CN), Blackpool Teaching Hospitals NHS Foundation Trust (GB), Instituto de Biomedicina de Sevilla (ES), Instituto de Investigación Biomédica de Salamanca (ES), Clinica Universidad de Navarra (ES), Johnson & Johnson (Israel) (IL), Centro de Investigación del Cáncer (ES), Johnson & Johnson (United Kingdom) (GB), Isala (NL), Hospital Privado (AR), Hospital Universitario Virgen del Rocío (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Klinik und Poliklinik für Psychotherapie und Psychosomatik (DE), Gdańsk Medical University (PL), University of Tübingen (DE), Hyogo University (JP), Sungkyunkwan University (KR), University of Bologna (IT), Stanford University (US)
Openalex Percentile: Top 1%
Multiple Myeloma Research and Treatments
15.93
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.